Population immunity and vaccine protection against infection

doi:10.1016/S0140-6736(21)00870-9

Comment

. 2021 May 8;397(10286):1685-1687.

doi: 10.1016/S0140-6736(21)00870-9. Epub 2021 Apr 23.

Population immunity and vaccine protection against infection

Eyal Leshem¹, Benjamin Alan Lopman²

Affiliations

¹ Infectious Diseases Unit, The Chaim Sheba Medical Centre, Ramat-Gan 52621, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: eyal.leshem@sheba.health.gov.il.
² Rollins School of Public Health, Emory University, Atlanta, GA, USA.

PMID: 33901422
PMCID: PMC8064666
DOI: 10.1016/S0140-6736(21)00870-9

Comment

Population immunity and vaccine protection against infection

Eyal Leshem et al. Lancet. 2021.

. 2021 May 8;397(10286):1685-1687.

doi: 10.1016/S0140-6736(21)00870-9. Epub 2021 Apr 23.

Authors

Eyal Leshem¹, Benjamin Alan Lopman²

Affiliations

¹ Infectious Diseases Unit, The Chaim Sheba Medical Centre, Ramat-Gan 52621, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: eyal.leshem@sheba.health.gov.il.
² Rollins School of Public Health, Emory University, Atlanta, GA, USA.

PMID: 33901422
PMCID: PMC8064666
DOI: 10.1016/S0140-6736(21)00870-9

No abstract available

PubMed Disclaimer

Figures

See this image and copyright information in PMC

Comment on

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.
Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J, Gillson N, Atti A, Islam J, Karagiannis I, Munro K, Khawam J, Chand MA, Brown CS, Ramsay M, Lopez-Bernal J, Hopkins S; SIREN Study Group. Hall VJ, et al. Lancet. 2021 May 8;397(10286):1725-1735. doi: 10.1016/S0140-6736(21)00790-X. Epub 2021 Apr 23. Lancet. 2021. PMID: 33901423 Free PMC article.

Cited by

COVID-19 vaccine impact in Israel and a way out of the pandemic.
Leshem E, Wilder-Smith A. Leshem E, et al. Lancet. 2021 May 15;397(10287):1783-1785. doi: 10.1016/S0140-6736(21)01018-7. Epub 2021 May 5. Lancet. 2021. PMID: 33964221 Free PMC article. No abstract available.
COVID-19 vaccination passport: prospects, scientific feasibility, and ethical concerns.
Sharun K, Tiwari R, Dhama K, Rabaan AA, Alhumaid S. Sharun K, et al. Hum Vaccin Immunother. 2021 Nov 2;17(11):4108-4111. doi: 10.1080/21645515.2021.1953350. Epub 2021 Jul 22. Hum Vaccin Immunother. 2021. PMID: 34292128 Free PMC article.
[Validation of COVID-19 vaccines administered abroad: experience and challenges of implementation in ChileRegistro de vacinação contra a COVID-19: experiência e desafios relacionados com a implementação no Chile].
Santos-López M, Alvear-Muñoz F, Arévalo-Galdames F, Díaz-Navarrete V. Santos-López M, et al. Rev Panam Salud Publica. 2023 Apr 14;47:e62. doi: 10.26633/RPSP.2023.62. eCollection 2023. Rev Panam Salud Publica. 2023. PMID: 37066127 Free PMC article. Spanish.
A comparative study of eight COVID-19 protective measures and their impact on Swiss tourists' travel intentions.
Hüsser AP, Ohnmacht T. Hüsser AP, et al. Tour Manag. 2023 Aug;97:104734. doi: 10.1016/j.tourman.2023.104734. Epub 2023 Jan 25. Tour Manag. 2023. PMID: 36712143 Free PMC article.
Primary Healthcare Providers' Views on Periodic COVID-19 Booster Vaccination for Themselves and Their Patients: A 2023 Nationwide Survey in Belgium.
Digregorio M, Van Ngoc P, Domen J, Bognar Z, Duysburgh E, Hendrickx G, Van Damme P, Coenen S, Scholtes B. Digregorio M, et al. Vaccines (Basel). 2024 Jul 3;12(7):740. doi: 10.3390/vaccines12070740. Vaccines (Basel). 2024. PMID: 39066378 Free PMC article.

See all "Cited by" articles

References

1. Gallagher ME, Sieben AJ, Nelson KN, et al. Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates. Nat Med. 2021;27:4–5. - PMC - PubMed
1. Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep. 2021;70:495–500. - PMC - PubMed
1. Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021 doi: 10.1038/s41591-021-01316-7. published online March 29. - DOI - PubMed
1. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397:875–877. - PMC - PubMed
1. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] Gallagher ME, Sieben AJ, Nelson KN, et al. Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates. Nat Med. 2021;27:4–5. - PMC - PubMed

[2] Gallagher ME, Sieben AJ, Nelson KN, et al. Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates. Nat Med. 2021;27:4–5. - PMC - PubMed

[3] Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep. 2021;70:495–500. - PMC - PubMed

[4] Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep. 2021;70:495–500. - PMC - PubMed

[5] Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021 doi: 10.1038/s41591-021-01316-7. published online March 29. - DOI - PubMed

[6] Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021 doi: 10.1038/s41591-021-01316-7. published online March 29. - DOI - PubMed

[7] Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397:875–877. - PMC - PubMed

[8] Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397:875–877. - PMC - PubMed

[9] Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. - PMC - PubMed

[10] Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Population immunity and vaccine protection against infection

Affiliations

Population immunity and vaccine protection against infection

Authors

Affiliations

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical